Uvax Bio

Uvax Bio, founded by Dr. Jiang Zhu, is a biotechnology company focused on developing innovative vaccines using its proprietary 1c-SApNP® platform technology. The company's core mission is to address unmet public health needs by creating virus-like particle vaccines through rational antigen design and protein engineering. Uvax Bio aims to become a global leader in the vaccine industry, targeting infectious disease threats with its advanced preventive technology.

Notable affiliated individuals include Dr. Jiang Zhu, who initiated his research at The Scripps Research Institute (TSRI) focusing on antibody discovery and rational vaccine design. Uvax Bio has garnered attention for its pioneering approach and has achieved significant milestones in vaccine development. The company's impact is marked by its potential to revolutionize the prevention of infectious diseases, contributing to global public health advancements.